BioSpace News Archive

VBL Therapeutics today announced that it will host a key opinion leader (KOL) luncheon and seminar on ovarian cancer on Monday, April 11, 2022 at 12pm Eastern Time at the St. Regis Hotel in New York, NY.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the launch of Save Legs.

Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that it has entered into an exclusive option and research collaboration agreement with Prime Medicine, Inc. (“Prime”), a company founded to deliver on the promise of Prime Editing.

Select Medical Holdings Corporation, will release the financial results for its first quarter ended March 31, 2022 on Thursday, May 5, 2022 after the market closes.

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the company will present research from its robust neurology portfolio, including the findings on lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody being developed for the treatment of early Alzheimer’s disease (AD) at the American Academy.

Nanox Announces Fourth Quarter 2021 Financial Results and Provides Business Update.

Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines, called prescription digital therapeutics, announced the company will participate in the Credit Suisse The Investor Landscape: Hidden Gems Conference on Thursday, April 7 in New York, NY.

Waters Corporation introduced the new Xevo™ TQ Absolute system, the most sensitive and compact benchtop tandem mass spec in its class.i This press release features multimedia.

Renegade.bio Announces Decision to Continue No-Cost COVID-19 Testing for Symptomatic, Uninsured Bay Area Community.

Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau.